lundi 7 décembre 2015

Onco Actu du 7 décembre 2015

3. Prévention

New medicines 'should prevent not just treat disease' [BBC News]

4.9 Dép., diag. & prono. - Sein

Early Detection of Breast Cancer Backed by U.K. Study [Wall Street Journal]

5.12 Immunothérapies

Jimmy Carter says brain cancer is gone following treatment [STAT]

New immunotherapy drug behind Jimmy Carter's cancer cure [The Guardian]

5.2 Pharma

Threshold Pharmaceuticals Announces Its Two Phase 3 Studies Evaluating Evofosfamide Did Not Meet Primary Endpoints [Threshold Pharmaceuticals]

5.2.1 Pharma - Partenariats

Merck and Amgen team up in immuno-oncology with a pair of combo trials [FierceBiotech]

5.3 Traitements - FDA, EMA,...

Rick's Search for Meaning [The Cancer Letter]

Mary Pazdur, 63, Dies of Cancer; What Her Husband Has Learned [The Cancer Letter]

5.4 Traitements - Economie

Rising Drug Costs to Be in Focus at Congressional Hearing [Wall Street Journal]

UK paying less for cancer drugs than other EU countries [PharmaTimes]

Harnessing The Immune System To Fight Cancer: 'Now We Can Offer Hope' [Forbes)

5.8 ASH

AbbVie, J&J leukemia drug cuts death risk vs chemo in new patients: study [Reuters]

5.8.1 ASH - Communiqués

Targeted Blood Cancer Therapies Offer Significant Improvements in Survival, Increased Options for Patients [ASH]

5.8.2 ASH - Pharma

Takeda Reports Five-Year Overall Survival Data For ADCETRIS® (Brentuximab Vedotin) Demonstrate Durable Remissions in Relapsed/Refractory Hodgkin Lymphoma [Takeda]

Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015 [Seattle Genetics]

New data from pivotal study showed Roche’s Gazyva/Gazyvaro induced deep remissions and provided meaningful quality of life improvements in people with difficult-to-treat indolent non-Hodgkin lymphoma [Roche]

AbbVie Announces New England Journal of Medicine Online Publication of Venetoclax Phase 1 Data in Relapsed/Refractory Chronic Lymphocytic Leukemia [AbbVie]

Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera [Novartis]

Novartis trial shows drug improves survival for AML patients [Reuters]

New results from CLL11 study show Gazyva/Gazyvaro provided people with previously untreated chronic lymphocytic leukaemia a treatment-free period of nearly four years [Roche]

5.8.4 ASH - CAR T

Novartis keeps its CAR-T lead with positive Phase II data [FierceBiotech]

Juno’s Investigational CAR T Cell Product Candidates JCAR014 and JCAR018 Demonstrate Encouraging Clinical Responses in Patients with B-Cell Cancers [Juno Therapeutics]

Novartis: Lymphoma study shows CART on track for 2017 U.S. submission [Reuters]

5.8.5 ASH - Myélome multiple

Takeda Presents Data from Phase 3 TOURMALINE-MM1 Study for NINLARO® (ixazomib), First and Only Once-Weekly Oral Proteasome Inhibitor Recently Approved for Multiple Myeloma [Takeda]

Ibrutinib (IMBRUVICA®) Combination Data Show Promise in Patients with Relapsed/Refractory Multiple Myeloma [AbbVie]

New Longer-Term Data for Empliciti (elotuzumab) Showed a Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma [BMS]

Experimental Gene Therapy Studies Show Promising Outcomes for Patients with Rare Blood Disorders and Cancer [ASH]

Bluebird (BLUE), Celgene (CELG) See Promise in T Cell Therapy for Multiple Myeloma [TheStreet]

6. Lutte contre les cancers

Tough Medicine [The New Yorker]